Vnitřní lékařství 3/2021

 Transformace IgM-MGUS do Waldenströmovy makroglobulinemie u 2 z 6 pacientů v průběhu léčby syndromu Schnitzlerové | E23 / Vnitř Lék 2021; 67(e3): e15–e23 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz LITERATURA 1. de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy 2014; 4: 41–45. 2. Mulla E, Neame R. Delayed development of the IgM paraprotein in Schnitzler’s syndro- me. Scand J Rheumatol 2015; 44: 521–522. 3. Willekens I, Walgraeve N, Goethals L et al. Correlative bone imaging in a case of Schnitzler’s syndrome and brief review of the literature. Hell J Nucl Med 2015; 18: 71–73. 4. Hrodek O. Schnitzler syndrome: an under-diagnosed clinical entity Transfuze a hema- tologie dnes. 2013; 19(4): 214–215. 5. Janíková-Obořilová, Adam Z. Schnitzlerův syndrom Vnitřní lék 1998; 44 (7): 423–4274. 6. Lipsker D, Veran Y, Grunenberger F et al. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001; 80: 37–44. 7. Simon A, Asli B, Braun-Falco M et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68: 562–568. 8. Kacar M, Pathak S, Savic S. Hereditary systemic autoinflammatory diseases and Schnitzler’s syndrome Rheumatology (Oxford) 2019; 58(Suppl 6): 31–43. 9. Basile C, Rossi L, Casucci F et al. Kidney involvement in the Schnitzler syndrome, a rare disease. Clin Kidney J. 2017; 10(6): 723–727. doi: 10.1093/ckj/sfx077. 10. Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clini- cal entity. Haematologica. 2013; 98(10): 1581–1585. doi: 10.3324/haematol.2013.084830. 11. Terpos E, Asli B, Christoulas D, Brouet J-C, Kastritis E, Rybojad M et al. Increased angio- genesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haemato- logica. 2012; 97(11): 1699–1703. 12. Niederhauser BD, Dingli D, Kyle RA, Ringler MD. Imaging findings in 22 cases of Schnitzler syndrome: characteristic Para-articular osteosclerosis, and the “hot knees” sign differen- tial diagnosis. Skeletal Radiol. 2014; 43(7): 905–915. 13. Darrieutort-Laffite C, Ansquer C, Aubert H et al.Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow-up data from a single-center co- hort of 25 patients. Arthritis Res Ther. 2020; 22(1): 272. doi: 10.1186/s13075-020-02318-5. 14. Alix L, Néel A, Cador B et al. Diagnostic value of 18-F fluorodeoxyglucose PET/CT and bone scan in Schnitzler syndrome. Autoimmunity. 2019; 52(7–8): 264–271.doi: 10.1080/08916934.2019.1680649. 15. Bursztejn AC, Imperiale A, Lipsker D. Aortitis: A new feature of Schnitzler syndrome. JAAD Case Rep. 2017; 3(5): 454–456. doi: 10.1016/j.jdcr.2017.06.016. PMID: 28971133; PM- CID: PMC5602823. 16. Kyle RA, Therneau TM, Rajkumar SV et al. Long-term follow-up of IgMmonoclonal gam- mopathy of undetermined significance. Blood. 2003; 102(10): 3759–3764. 17. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopatho- logical definition of Waldenstrom’s macroglobulinemia: consensus panel recommenda- tions from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003; 30(2): 110–115. 18. Elba S, Castellino A, Soriasio R et al. Immunoglobulin M (IgM) multiple myeloma ver- sus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. J Med Case Rep. 2020; 14(1): 75. doi: 10.1186/s13256-020-02380-2. PMID: 32564775; PMCID: PMC7310052. 19. Gerz MA: Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratifica- tion, and management. Amer J Hematol. 2021; 96(2): 258–269. 20. Gavriatopoulou M, Musto P, Caers J et al. European myeloma network recommen- dations on diagnosis and management of patients with rare plasma cell dyscrasias. Le- ukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. PMID: 30038381. 21. Kastritis E, Leblond V, Dimopoulos MA, ESMO Clinical Practice Guidelines for diagnosis, tre- atment and follow-up. Ann Oncol. 2018; 29(Suppl 4): iv41–iv50. doi: 10.1093/annonc/mdy146. 22. Aouba A, Pressiat C, Pricopi M et al. Complete remission of Schnitzler syndrome and Waldenströmmacroglobulinemia under rituximab-cyclophosphamide-dexamethasone. Dermatology 2015; 230(1): 18–22. 23. Cascavilla N, Bisceglia M, D’Arena G. Successful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trial. Int J Immunopathol Pharmacol 2010; 23(2): 633–636. 24. Murota H, Shoda Y, Ishibashi T et al. Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. J Am Acad Dermatol 2009; 61(6): 1070–1075. 25. Eiling E, Möller M, Kreiselmaier I et al. Schnitzler syndrome: treatment failure to rituxi- mab but response to anakinra. J Am Acad Dermatol 2007; 57(2): 361–364. 26. Ramadan KM, Eswedi HA, El-Agnaf MR. Schnitzler syndrome: a case report of suc- cessful treatment using the anti-CD20 monoclonal antibody rituximab. Br J Dermatol 2007; 156(5): 1072–1074. 27. Husak R, Nestoris S, Goerdt S et al. Severe course of chronic urticaria, arthralgia, fever and elevation of erythrocyte sedimentation rate: Schnitzler’s syndrome without monoc- lonal gammopathy? Br J Dermatol 2000; 142: 581–582. 28. Cristina T, Varella N, Nishimura MY et al. Schnitzler’s syndrome without monoclonal gammopathy. Acta Derm Venereol 2005; 85: 272–273. 29. Jani P, Vissing MB, Ahmed S et al. Ibrutinib for the Management of Schnitzler Syndro- me: A Novel Therapy for a Rare Condition. J Oncol Pract. 2018; 14(6): 387–388. doi: 10.1200/ JOP.18.00050. Epub 2018 Mar 20. 30. Doležalová P. Nové indikace léčby anakinrou Farmakoterapie (Praha, Print) 2019; 15(3): 333–337. 31. Šedivá, A, Slíva J, Doležalová P et al. Anakinra Farmakoterapie (Praha, Print) 2011; 7(6): 621–629. 32. Néel A, Henry B, Barbarot S et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: A French multicenter study. Au- toimmun Rev 2014; 13: 1035–1041. 33. Rowczenio DM, Pathak S, Arostegui JI et al. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood. 2018; 131(9): 974–981. doi:10.1182/blood-2017-10-810366. 34. Vanderschueren S, van der Veen A. The Schnitzler syndrome: chronic urticaria in dis- guise: a single-centre report of 11 cases and a critical reappraisal of the literature. Clin Exp Rheumatol. 2017; 35(1): 69–73. 35. Giurgea I, Grateau G, Georgin-Lavialle S; French Network of Dysimmune Disorders Associated with Hemopathies. Monoclonal Gammopathy, Arthralgias, and Recurrent Fe- ver Syndrome: A New Autoinflammatory Syndrome? J Rheumatol. 2019; 46(11): 1535–1539. doi: 10.3899/jrheum.181204. 36. Soudet S, Fajgenbaum D, Delattre C et al. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case re- port and clue to pathophysiology. Curr Res Transl Med. 2018; 66(3): 83–86. doi: 10.1016/j. retram.2018.06.001. 37. Gorodetskiy VR, Salugina SO, Fedorov ES. Increasing the Interval of Canakinumab Ad- ministration Effectively Supports the Remission of Schnitzler’s Syndrome. Case Rep Rheu- matol. 2018;2018:5416907. doi: 10.1155/2018/5416907. PMID: 29850358; PMCID: PMC5925130. 38. Fujita Y, Asano T, Sakai A et al. A case of Schnitzler’s syndrome without monoclo- nal gammopathy successfully treated with canakinumab. BMC Musculoskelet Disord. 2021;22(1):257. doi: 10.1186/s12891-021-04120-z. Betrains A, Staels F, Vanderschueren S. Effi- cacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. Semin Arthritis Rheum. 2020; 50(4): 636–642. doi: 10.1016/j.semarthrit.2020.05.002. 39. Krause K, Tsianakas A, Wagner N et al. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. J Allergy Clin Immunol. 2017; 139(4): 1311–1320. 40. Krause K, Bonnekoh H, Ellrich A et al. Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome. J Allergy Clin Immunol. 2020; 145(6): 1681–1686.e5. doi:10.1016/j.jaci.2019.12.909. 41. Betrains A, Staels F, Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. Semin Arthritis Rheum. 2020; 50(4): 636–642. doi: 10.1016/j.semarthrit.2020.05.002. 42. Krause K, Feist E, Fiene M et al. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012; 129: 848–850. 43. Claus J, Vanderschueren S. Variable Responses to Tocilizumab in Four Patients with Schnitzler Syndrome. J Clin Immunol 2019; 39(4): 370–372. 44. Yan R, Cao W, Liu X, Li F, Shen M. A Chinese case series of Schnitzler syndrome and com- plete remission in one tocilizumab-treated patient. Clin Rheumatol. 2020; 39(12): 3847–3852. 45. Kluger N, Bessis D, Guillot B. Tocilizumab as a potential treatment in Schnitzler syndro- me. Med Hypotheses 2009; 72(4): 479–480. 46. Więsik-Szewczyk E, Felis-Giemza A et al. Schnitzler Syndrome in a 27-Year-Old Man: Diagnostic and Therapeutic Dilemma in Adult Auto-Inflammatory Syndromes A Case Re- port and Literature Review. Int J Gen Med. 2020; 13: 713–719. doi: 10.2147/IJGM.S265482 47. Bonnekoh H, Frischbutter S, Roll S et al. Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study. J Allergy Clin Immunol Pract. 2021; S2213–2198(21)00152- 5. doi: 10.1016/j.jaip.2021.01.024. 48. Castillo JJ, Advani RH, Branagan AR et al. Consensus treatment recommendations from the tenth International Workshop for WaldenströmMacroglobulinaemia. Lancet Haema- tol. 2020; 7(11): e827–e837. doi:10.1016/S2352-3026(20)30224-6. 49. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA et al. Recommendations for the diagno- sis and initial evaluation of patients with WaldenströmMacroglobulinaemia: A Task Force from the 8th International Workshop on WaldenströmMacroglobulinaemia. Br J Haema- tol. 2016; 175(1): 77–86. doi: 10.1111/bjh.14196.